| Literature DB >> 35450507 |
Sze-Wen Ting1, Jia-Jin Chen2, Tao-Han Lee2,3, George Kuo2.
Abstract
Infective endocarditis (IE) is a serious infection and causes significant morbidity and mortality. However, the benefit of surgery for endocarditis besides antibiotic treatment in dialysis patients remains controversial. We performed a systematic review of studies published between 1960 and February 2022. Meta-analysis was conducted with a random-effects model to explore the in-hospital, 30, 60, 90, 180-d, and 1-year mortality rates in adult dialysis patients with IE. Sensitivity analysis, subgroup analysis, and meta-regression were performed to explore potential sources of heterogeneity. Confidence of evidence was evaluated by the GRADE system. Thirteen studies were included. The pooled odds ratio of in-hospital mortality was 0.62 (95% confidence interval [CI]: 0.30-1.28, p = .17), with moderate heterogeneity (I2 = 62%, p < .01). Three studies reported 30-d mortality, and the pooled odds ratio for surgery compared with medical treatment was even lower (0.36; 95% CI: 0.22-0.61, p < .01), with low heterogeneity (I2 = 0%, p = .86). With studies on fewer than 30 patients excluded, the sensitivity analysis revealed a low odds ratio of in-hospital mortality for surgery versus medical treatment (0.52; 95% CI: 0.27-0.99, p = .047), with moderate heterogeneity (I2 = 63%, p < .01). Subgroup analysis revealed no significant differences between any two comparator subgroups. Based on a very low strength of evidence, compared with medical treatment, surgical treatment for IE in patients on dialysis is not associated with lower in-hospital mortality. When studies on fewer than 30 patients were excluded, surgical treatment was associated with better survival.Entities:
Keywords: Dialysis; infective endocarditis; mortality; valve replacement surgery; valvuloplasty
Mesh:
Substances:
Year: 2022 PMID: 35450507 PMCID: PMC9037223 DOI: 10.1080/0886022X.2022.2064756
Source DB: PubMed Journal: Ren Fail ISSN: 0886-022X Impact factor: 3.222
Figure 1.PRISMA flow diagram of literature search, exclusion, and inclusion.
Characteristics of included studies.
| Study | Design | Exclusion of Duke possible IE | Mean age | Male | Diabetes mellitus | Heart failure | Embolization | New-onset valve dysfunction | Prosthetic IE | Prior IE | Invasion beyond valve leaflet | Large mobile vegetation | Persistent sepsis 5–7 days despite adequate antibiotics | Follow up duration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| [ | Retrospective cohort | Not exclude | 55 | 30% | 45% | NR | 40% | 5% | 5% | NR | NR | NR | NR | Till discharge |
| [ | Retrospective cohort | Not exclude | 60.70% | 28.50% | 42.90% | 17.80% | NR | NR | NR | NR | NR | NR | 1 year | |
| [ | Retrospective cohort | Exclude | 60 | 52% | 42% | NR | 28.80% | NR | 0% | 12% | NR | NR | NR | 5 years |
| [ | Retrospective cohort | Exclude | 56 | 45% | 37.70% | 30.40% | 50.70% | 56% | 4.30% | NR | 7.20% | NR | NR | Till discharge |
| [ | Retrospective cohort | Exclude | 57.3 | 47% | 59% | NR | 28.80% | NR | 2% | 10.20% | NR | NR | NR | 1 years |
| [ | Retrospective cohort | Not exclude | 52.5 | 62.50% | 6.20% | 56.20% | 18.70% | 50% | NR | 12.50% | 37.50% | NR | Up to 21.7 months | |
| [ | Retrospective cohort | Exclude | 55.3 | 52% | 33.30% | NR | 12% | 21.40% | 9.50% | 9.50% | NR | NR | NR | 5 years |
| [ | Retrospective cohort | Not exclude | 62.12 | 47% | 59.40% | NR | NR | NR | NR | 0% | NR | NR | NR | 9 years |
| [ | Retrospective cohort | Not exclude | NR | NR | NR | NR | 29.80% | NR | NR | NR | NR | 53.10% | NR | 3 years |
| [ | Prospective cohort | Exclude | 66 | 69% | 42.90% | 40.50% | 52.40% | 33% | 23.80% | 7.10% | 9.50% | NR | NR | Till discharge |
| [ | Retrospective cohort | Not exclude | 55 | 63% | 43% | NR | NR | NR | NR | NR | 47% | NR | NR | 12 years |
| [ | Retrospective cohort | Not exclude | 64.2 | 45.70% | 54.30% | 31.90% | 23.30% | NR | NR | NR | NR | NR | NR | 5 years |
| [ | Prospective cohort | Not exclude | 59.9 | 41.40% | 41.20% | 25.90% | 18.80% | 52.50% | 14% | 11.80% | 13.1 | NR | 22.40% | 1 year |
IE: infective endocarditis; NR: not reported.
Outcomes in included studies.
| Author | Year | Patient | In-hospital death | 30-d death | 90-d death | 180-d death | 1 year-death | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Surgical | Medical | Surgical | Medical | Surgical | Medical | Surgical | Medical | Surgical | Medical | |||
| Robinson | 1997 | 20 | 2/5 | 4/15 | ||||||||
| Doulton | 2003 | 30 | 1/15 | 8/15 | 3/15 | 8/15 | ||||||
| Nori | 2006 | 52 | 5/12 | 14/40 | ||||||||
| Kamalakannan | 2007 | 69 | 3/15 | 31/54 | ||||||||
| Baroudi | 2008 | 59 | 1/7 | 16/52 | 1/7 | 21/52 | 5/7 | 31/52 | ||||
| Rekik | 2009 | 16 | 4/5 | 3/11 | ||||||||
| Jones | 2013 | 42 | 1/9 | 5/33 | 1/9 | 6/33 | 1/9 | 6/33 | 1/9 | 8/33 | ||
| Chou | 2015 | 502 | 11/39 | 107/463 | ||||||||
| Powell | 2015 | 258 | 11/68 | 61/190 | ||||||||
| Durante-Mangoni | 2016 | 42 | 3/16 | 8/26 | ||||||||
| Raza | 2017 | 173 | 18/144 | 11/29 | 56/126 | 5/18 | ||||||
| Liau | 2021 | 116 | 10/29 | 50/87 | ||||||||
| Pericas | 2021 | 553 | 53/168 | 113/385 | 68/168 | 150/385 | ||||||
Figure 2.Pooled in-hospital mortality rate after infective endocarditis in patients with kidney failure.
Newcastle–Ottawa Scale risk of bias of included studies.
| Selection | Comparability | Outcome | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Representativeness of the exposed cohort | Selection of the non-exposed cohort | Ascertainment of exposure | Demonstration that outcome of interest was not present at start of study | Comparability of cohorts on the basis of the design or analysis | Assessment of outcome | Was follow-up long enough for outcomes to occur | Adequacy of follow up of cohorts | Overall risk of bias | |
| [ | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | High |
| [ | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | High |
| [ | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | High |
| [ | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | High |
| [ | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | High |
| [ | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | High |
| [ | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | High |
| [ | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | High |
| [ | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | High |
| [ | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | High |
| [ | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | High |
| [ | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | High |
| [ | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | High |
Figure 3.Results of subgroup analysis of the effects of potentially interacting factors on in-hospital mortality.